肝移植前后的丙型肝炎病毒直接作用药物。
Direct-acting agents for hepatitis C virus before and after liver transplantation.
机构信息
Departments of Transplantation/Pediatric Surgery and Gastroenterology and Hepatology, Postgraduate School of Life Science, Kumamoto University.
出版信息
Biosci Trends. 2018 Jan 9;11(6):606-611. doi: 10.5582/bst.2017.01293. Epub 2017 Dec 14.
Chronic hepatitis C virus (HCV) infection remains a widespread public health concern and many people are infected with HCV. HCV is one of the leading indications for liver transplantation. Direct-acting antiviral agents (DAAs) against HCV have changed the course of chronic HCV infection, however, making it a curable disease. DAA treatment may be initiated before or after liver transplantation. In the present review, we present the available data on DAA treatment of HCV in liver transplant recipients.
慢性丙型肝炎病毒 (HCV) 感染仍然是一个广泛存在的公共卫生问题，许多人感染了 HCV。HCV 是肝移植的主要适应证之一。针对 HCV 的直接作用抗病毒药物 (DAA) 改变了慢性 HCV 感染的进程，使其成为一种可治愈的疾病。DAA 治疗可以在肝移植之前或之后开始。在本综述中，我们介绍了肝移植受者 HCV 的 DAA 治疗的现有数据。
Zotero 插件